Acumen Pharmaceuticals (NASDAQ: ABOS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-15 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.170 | -0.230 | -0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Other companies in Acumen Pharmaceuticals’s space includes: Molecular Partners (NASDAQ:MOLN), Macrogenics (NASDAQ:MGNX), Impel Pharmaceuticals (NASDAQ:IMPL), Innate Pharma (NASDAQ:IPHA) and KalVista Pharmaceuticals (NASDAQ:KALV).
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by HC Wainwright & Co. on Thursday, June 30, 2022. The analyst firm set a price target for 15.00 expecting ABOS to rise to within 12 months (a possible 172.73% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $5.5 last updated July 6, 2022, 8:00 PM UTC.
There are no upcoming dividends for Acumen Pharmaceuticals.
Acumen Pharmaceuticals’s Q2 earnings are confirmed for Monday, August 15, 2022.
There is no upcoming split for Acumen Pharmaceuticals.
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.